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Objective
To determine the impact of prostate size on positive
surgical margin (PSM) rates after robot-assisted radical
prostatectomy (RARP) and the preoperative factors
associated with PSM.
Patients and Methods
In all, 1229 men underwent RARP by a single surgeon, from
2005 to August of 2013. Excluded were patients who had
transurethral resection of the prostate, neoadjuvant therapy,
clinically advanced cancer, and the ﬁrst 200 performed cases
(to reduce the eﬀect of learning curve). Included were 815
patients who were then divided into three prostate size
groups: <31 g (group 1), 31–45 g (group 2), >45 g (group 3).
Multivariate analysis determined predictors of PSM and
biochemical recurrence (BCR).
Results
Console time and blood loss increased with increasing
prostate size. There were more high-grade tumours in group 1
(group 1 vs group 2 and group 3, 33.9% vs 25.1% and 25.6%,
P = 0.003 and P = 0.005). PSM rates were higher in prostates
of <45 g with preoperative PSA levels of >20 ng/dL, Gleason
score ≥7, T3 tumour, and ≥3 positive biopsy cores. In group 1,
preoperative stage T3 [odds ratio (OR) 3.94, P = 0.020] and ≥3
positive biopsy cores (OR 2.52, P = 0.043) were predictive of
PSM, while a PSA level of >20 ng/dL predicted the occurrence
of BCR (OR 5.34, P = 0.021). No preoperative factors
predicted PSM or BCR for groups 2 and 3.
Conclusion
A preoperative biopsy with ≥3 positive cores in men with
small prostates predicts PSM after RARP. In small prostates
with PSM, a PSA level of >20 ng/dL is a predictor of BCR.
These factors should guide the choice of therapy and indicate
the need for closer postoperative follow-up.
Keywords
prostate, prostatic neoplasms, prostatectomy, surgical
margins
Introduction
The size of the prostate still remains a factor that inﬂuences
choice of and delivery of surgical treatment for prostate cancer
and has been shown to be associated with surgical and
oncological outcomes [1–3]. Large glands have been associated
with more diﬃcult prostate surgery but more favourable
oncological results [4,5], while small glands have been
associated with shorter surgery but worse oncological results
[6,7].
It has been suggested that the sudden surge in the use of
robotic technology with its greatly magniﬁed view and
three-dimensional vision has allowed us to overcome the
limitations resulting from prostate size [8,9]. However,
more data are needed to give credence to this assumption.
Consequently, there is a need to identify which preoperative
characteristics inﬂuence oncological outcomes after
robot-assisted radical prostatectomy (RARP). Such factors are
not only important in preoperative planning and managing
patient expectations, but should be valuable in designing
follow-up schemes and deciding on further therapy after
surgery.
The present study determined the impact of prostate size on
the oncological outcomes and preoperative factors that predict
positive surgical margin (PSM) and biochemical recurrence
(BCR) in patients with PSM after RARP.
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Patients and Methods
This was a retrospective analysis of 1229 men who underwent
RARP, performed by a single surgeon from 2005 to August of
2013, in a single high-volume tertiary institution.
To reduce the learning curve bias, we excluded our ﬁrst 200
cases from this study.We also excluded 60 patients who had
previous TURP, 43 who had preoperative neoadjuvant therapy,
and 111 with clinically advanced (N1 or M1 via preoperative
MRI and/or bone scan) prostate cancer. The 815 patients who
were included in this study were then divided into tertiles
based on prostate size as follows: <31 g (group 1, n = 271),
31–45 g (group 2, n = 271), >45 g (group 3, n = 273).We based
our prostate size groupings on the pathological prostate
weight instead of the TRUS volume for more accurate
measurements.
RARP was performed as previously described [10]. Pelvic
lymph node dissection was performed for patients with
intermediate- to high-risk cancer based on the D’Amico
classiﬁcation. Bilateral nerve-sparing surgery (NSS) was done
routinely for localised cancer and was performed in locally
advanced cancer as long as the frozen section analysis was
negative. Pathological analysis of the specimen was performed
by a dedicated team of pathologists and the ﬁndings were
prospectively collected in an electronic database.
The three groups were compared based on perioperative,
pathological and oncological characteristics.With a few
exceptions, a 12-core prostate biopsy was routinely taken in
our institution. Preoperative MRI was done routinely in all
patients for the purpose of tumour staging. The primary
endpoint of this study was PSM rates in the diﬀerent prostate
size groups. PSM rates were compared across groups based on
preoperative characteristics [PSA level, biopsy Gleason score,
number of positive biopsy cores, maximum percentage of
tumour per biopsy core, and extraprostatic extension (EPE)
on preoperative MRI], location, and level of nerve-sparing
technique.We categorically classiﬁed the number of positive
biopsy cores into <3 and >3 based on the computed overall
median value. BCR in patients with PSM was a secondary
endpoint. BCR was deﬁned as two consecutive PSA levels of
>0.02 ng/dL.
Our patients followed a standardised follow-up schedule
composed of monthly follow-ups for the ﬁrst 6 months after
RARP, a follow-up at 12 months, then yearly follow-ups as
needed. Each visit included a PSA measurement. An MRI was
taken commonly on the third month of follow-up as part of
the patient insurance package. MRI was also used to conﬁrm
suspicions of tumour recurrence or metastasis and in patients
suspected of having infected lymphoceles.
We used SPSS to divide the prostate sizes into tertiles. The
mean and standard deviation (SD) were used to describe
continuous variables. Comparative tests (Student’s t-test,
chi-squared test) were used to compare continuous and
categorical variables. Univariate and multivariate analyses were
used to determine the preoperative predictors of PSM both in
the overall study population and in patients who had NSS.
Univariate and multivariate analysis determined the predictors
of BCR overall and BCR only in patients with PSM. Statistical
signiﬁcance was set at P < 0.050 for all two-sided tests. All
statistical analyses were performed using SPSS version 20
(IBM Corp., Armonk, NY, USA). This study was approved by
our Institutional Review Board.
Results
Table 1 describes the preoperative, perioperative, pathological
and oncological characteristics of patients. The three groups
were similar in terms of preoperative characteristics except for
PSA levels, which was highest in group 3 (>45 g glands).
Although mean blood loss was higher in prostates weighing
>45 g, only nine patients required blood transfusion
postoperatively. Compared with prostates >31 g, prostates
measuring <31 g had more PSM regardless of pathological T
stage.
The characteristics of PSM based on preoperative, pathological
and oncological parameters are given in Table 2. The tumour
volumes were not signiﬁcantly diﬀerent for each category of
prostate size. The largest tumour volumes for each group were
all found in patients who had high-grade (Gleason scores 8, 9
and 9) and pathological T3 disease. The overall PSM rate,
regardless of pathological T stage or type of NSS performed
was 13.9%. The relative risk of PSM after NSS, compared with
patients who did not have NSS, for groups 1–3 were 2.93 (95%
CI 1.25–6.96, P = 0.010), 2.00 (95% CI 0.79–5.09, P = 0.136)
and 2.10 (95% CI 0.83–5.27, P = 0.109), respectively. NSS was
performed in 69.4%, 69.0%, 71.4% of glands in groups 1–3,
respectively. There were PSMs in 19 of 245 (6.9%) men who
did not have NSS. They were all aged >65 years, had palpable
disease, and biopsy Gleason scores ≥7. For each grouping
based on prostate size, the most common location of PSM was
in the apex. However, when comparing the three groups,
apically located PSM occurred signiﬁcantly more frequently in
Group 1.
Table 3 describes the preoperative predictors of PSM.
Multivariate analysis was not performed for prostate size
>45 g because only one variable (PSA level >20 ng/dL) was
signiﬁcant during univariate analysis.
Multivariate analysis revealed that PSA level [odds ratio (OR)
1.04, 95% CI 1.02–1.05; P < 0.001), PSM (OR 2.15, 95% CI
1.37–3.35, P = 0.001) and clinical T stage (OR 1.519, 95% CI
1.38–1.68, P < 0.001) were predictors of BCR overall. For
group 1, PSM (OR 2.41, 95% CI 1.11–5.25, P = 0.027), and
clinical T stage (OR 1.36, 95% CI 1.14–1.62, P = 0.001) were
predictors of BCR. For group 2, clinical T stage (OR 1.39, 95%
CI 1.13–1.72, P = 0.002) and biopsy Gleason score (OR 3.51,
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95% CI 2.28–5.37, P < 0.001) were predictors of BCR. For
group 3, PSA level (OR 1.031, 95% CI 1.01–1.05, P = 0.003),
clinical T stage (OR 2.09, 95% CI 1.35–3.24, P = 0.001) and
biopsy Gleason score (OR 2.13, 95% CI 1.40–3.06, P < 0.001)
were predictors of BCR. PSM was not a predictor of BCR in
Groups 2 and 3.
Table 4 describes the predictors of BCR in PSM-positive cases.
BCR occurred in 30.4% of men who were found to have PSM
overall. The mean (SD) follow-up durations were 18.1 (13.53),
18.2 (13.43), and 18.5 (13.49) months for groups 1–3,
respectively and were not signiﬁcantly diﬀerent from each
other.
Discussion
In terms of the eﬀect of prostate size on various clinical and
perioperative parameters, our present results are in agreement
with most previous articles [11–13]. Increasing body mass
index has been linked to larger prostate glands in men with
localised prostate cancer and has been attributed to obesity
related inﬂammatory changes [14,15]. Higher PSA levels in
larger glands are probably due to increased PSA production
by the adenoma rather than a reﬂection of tumour
aggressiveness. The longer mean operative time and greater
intraoperative blood loss in larger glands mirrors the degree of
diﬃculty of the surgery. Surgery on larger glands is more
Table 1 Comparison of pre- and perioperative, pathological and oncological characteristics.
Characteristic Prostate size, g P1 P2 P3
<31 (Group 1) 31–45 (Group 2) >45 (Group 3)
Number of patients 271 271 273
Mean (SD) age, years 62.4 (8.23) 63.7 (6.7) 62.6 (6.4) 0.711 0.645 0.802
Mean (SD) PSA level, ng/dL 8.7 (10.23) 11.0 (13.21) 14.0 (17.08) <0.001* <0.001* <0.001*
D’Amico Classiﬁcation, n (%) 0.964 0.912 0.897
Low risk 51 (18.5) 51 (18.5) 49 (17.6)
Intermediate risk 57 (21.4) 60 (22.1) 66 (24.3)
High risk 163 (60.1) 160 (59.4) 158 (58.3)
Biopsy Gleason score, n (%) 0.354 0.219 0.412
6 111 (41.0) 106 (39.1) 109 (39.9)
7 95 (35.1) 90 (33.2) 95 (34.8)
≥8 65 (24.0) 75 (27.7) 69 (25.3)
Mean (SD) number of positive biopsy cores 3.81 (2.90) 3.89 (2.88) 3.54 (2.86) 0.655 0.407 0.703
Maximum % cancer per core, n (%)
>25 183 (67.5) 173 (63.8) 163 (26.6) 0.185 0.527 0.493
>50 138 (50.9) 131 (48.3) 129 (47.2) 0.400 0.533 0.832
>75 64 (23.6) 62 (22.9) 58 (21.2) 0.753 0.601 0.833
EPE on MRI, n (%) 126 (46.5) 129 (47.6) 142 (52.0) 0.613 0.502 0.859
Mean (SD) console time, min 179.9 (46.5) 187.7 (39.6) 198.9 (50.1) <0.001* <0.001* <0.001*
Mean (SD) blood loss, mL 270.4 (206.9) 260.1 (189.3) 318.7 (240.8) 0.493 <0.001* <0.001*
Mean (SD) tumour volume, mL 2.31 (3.7) 3.5 (6.9) 2.88 (4.5) 0.103 0.162 0.692
Pathological Gleason score, n (%) 0.003* 0.005* 0.832
6 70 (25.8) 67 (24.7) 68 (24.9)
7 109 (40.2) 136 (50.2) 135 (49.5)
≥8 92 (33.9) 68 (25.1) 70 (25.6)
Pathological T stage, n (%) 0.700 0.719 0.450
pT2 162 (59.8) 157 (57.9) 168 (61.5)
pT3 109 (40.2) 114 (42.1) 105 (38.5)
PSM, n (%)
Overall 47 (17.3) 35 (12.9) 31 (11.4) 0.004* <0.001* 0.266
pT2 stage 13/162 (8.0) 7/157 (4.5) 9/168 (5.5) 0.008* 0.042* 0.504
pT3 stage 32/109 (29.4) 32/114 (21.1) 19/105 (18.1) 0.005* <0.001* 0.272
PSM location overall, n (%)
Apex 22 (8.1) 16 (5.9) 12 (4.4) 0.043* <0.001* 0.112
Base 3 (1.1) 5 (1.8) 4 (1.5) 0.155 0.459 0.488
Lateral 14 (5.2) 9 (3.3) 7 (2.6) 0.033* 0.002* 0.297
Anterior 3 (1.1) 3 (1.1) 2 (0.7) 1.000 0.361 0.361
Posterior 3 (1.1) 1 (0.4) 3 (1.1) 0.064 1.000 0.064
Bladder neck 4 (1.5) 2 (1.1) 3 (1.1) 0.442 0.095 0.361
BCR, n (%)
Overall 50 (18.5) 54 (19.9) 52 (19.1) 0.384 0.691 0.635
pT2 stage 15/162 (9.3) 13/157 (8.3) 12/7.1 (18.5) 0.742 0.489 0.721
pT3 stage 23/109 (29.5) 27/114 (34.6) 26/105 (32.9) 0.176 0.359 0.655
With PSM 15/47 (31.9) 11/35 (31.4) 9/31 (29.0) 0.926 0.590 0.677
Mean (SD) time to BCR, months 31.30 (16.69) 35.27 (14.49) 34.66 (14.22) 0.361 0.254 0.504
*Signiﬁcant; P1, Group 1 vs Group 2; P2, Group 1 vs Group 3; P3, Group 2 vs Group 3; BMI, body mass index.
Prostate size and PSM rates after RARP
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complicated because of a limited space to manoeuvre,
diﬃculty in separating the prostate from the bladder due to
the presence of a median lobe, more diﬃcult neurovascular
bundle dissection and increased need for bladder
reconstruction [16,17].
The issue about the eﬀect of prostate size on oncological
results has revolved mostly around its eﬀect on PSM rates. In
the study by Marchetti et al. [18] of 690 patients with low-risk
prostate cancer who underwent bilateral nerve-sparing RARP,
lower prostate weight was shown to have a higher probability
of PSM. In the study by Skolarus et al. [19], prostates weighing
>50 g, when compared with those weighing <50 g, were not
associated with increased incidence of PSM. Our present study
reports an overall PSM rate of 17.3%, 12.9% and 11.4% % in
groups 1–3 respectively, which are consistent with previously
reported PSM rates ranging from 22% to 43% [18,20].
However, prudence should be exercised in interpreting these
values given the lack of a standardised classiﬁcation of
prostate size.
While the association of increased PSM with smaller prostates
has largely been explained by lead-time bias, our present data
are more consistent with the theory that cancer in small
prostates has diﬀerent biological activity. In contrast to
previous studies reporting more advanced age in men with
larger prostates [17,19], our present study failed to ﬁnd
signiﬁcant diﬀerences in age between prostate size groups,
hence making lead-time bias less likely. The impact of surgical
skill and learning curve on PSM rates has previously been
raised [21], but excluding our ﬁrst 200 cases should have
negated this factor.
In their study of 700 post-RARP patients, Yadav et al. [22]
found a higher incidence of EPE and PSM in small prostates
(40 g) compared with glands weighing 40–70 and >70 g.
In a more recent study, Labanaris et al. [23] performed a
matched-pair analysis on the results of RARP in men
with <50 and >100 g prostates. They reported that men with
smaller prostates had larger tumour volumes, were less
organ-conﬁned, had more EPE and had more BCR. These
Table 2 PSM based on preoperative characteristics, pathological characteristics and level of nerve-sparing.
PSM in patients with the
following characteristics
Prostate size, g P1 P2 P3
<31 (Group 1) 31–45 (Group 2) >45 (Group 3)
n/N (%):
Preoperative PSA level (ng/dL):
>10 29/72 (40.3) 13/81 (16.0) 17/111 (15.3) <0.001* <0.001* 0.784
<10 18/199 (9.0) 22/253 (8.7) 14/162 (8.6) 0.611 0.554 0.813
>20 21/32 (65.6) 10/31 (32.2) 10/46 (21.7) 0.047* 0.022* 0.053
<20 26/239 (10.9) 25/240 (10.4) 21/227 (9.3) 0.755 0.412 0.302
Biopsy Gleason score:
<7 12/111 (10.8) 9/106 (8.5) 9/109 (8.3) 0.125 0.188 0.840
>7 35/160 (21.9) 26/165 (16.3) 22/164 (13.5) 0.009* <0.001* 0.165
Clinical T stage:
cT1 9/119 (7.5) 9/126 (7.1) 8/153 (5.2) 0.155 0.055 0.061
cT2 11/73 (15.1) 11/67 (16.4) 10/65 (15.4) 0.947 0.267 0.306
cT3 27/79 (22.8) 15/78 (19.2) 13/88 (14.8) 0.010* 0.007* 0.169
D’Amico risk:
Low 5/51 (9.8) 4/51 (7.8) 5/49 (10.2) 0.201 0.823 0.145
Intermediate 20/57 (35.1) 17/60 (28.3) 12/66 (18.2) 0.766 0.403 0.320
High 22/163 (13.5) 24/160 (15.0) 14/158 (8.9) 0.552 0.264 0.330
Number of positive biopsy cores:
<3† 14/145 (9.7) 14/140 (10.0) 11/135 (8.1) 0.885 0.622 0.419
>3† 32/126 (25.4) 21/131 (16.0) 20/138 (14.5) 0.002* <0.001* 0.543
Maximum % cancer per core:
>25 31/183 (16.9) 28/173 (16.2) 25/163 (15.3) 0.848 0.327 0.435
>50 25/138 (18.1) 23/131 (17.6) 23/129 (17.8) 0.905 0.355 0.425
>75 11/64 (17.2) 13/62 (20.9) 10/58 (17.2) 0.589 0.994 0.604
EPE on MRI 126 (46.5) 129 (47.6) 142 (52.0) 0.613 0.502 0.859
Pathological T stage:
pT2 13/162 (8.0) 7/157(4.5) 9/168 (5.5) 0.008* 0.042* 0.504
pT3 32/109 (29.4) 24/114 (21.1) 19/105 (18.1) 0.005* <0.001* 0.272
NSS:
Yes 40/188 (21.3) 25/187 (13.4) 29/195 (14.8) 0.032* 0.044* 0.410
No 7/83 (8.4) 6/84 (7.1) 6/78 (7.6) 0.097 0.498 0.267
Level of nerve-sparing:
Intra-fascial 31/118 (26.3) 21/119 (17.6) 23/136 (16.9) 0.027* 0.002* 0.663
Inter-fascial 3/15 (20.0) 2/12 (16.7) 3/17 (17.6) 0.079 0.118 0.541
Extra-fascial 6/55 (10.9) 4/56 (7.1) 3/42 (7.1) 0.211 0.116 0.813
*Signiﬁcant; †Median split; P1, Group 1 vs Group 2; P2, Group 1 vs Group 3; P3, Group 2 vs Group 3.
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studies focused on pathological variables and did not establish
a direct relationship between preoperative factors and PSM. In
their study of 876 patients who underwent RARP, Coelho et al.
[24] reported PSA as the only preoperative variable associated
with PSM, but prostate size was not accounted for. In our
present study, having ≥3 positive biopsy cores and a T3
tumour in small prostates predicted PSM after RARP, but
failed to do so for 31–45 and >45 g prostates. More positive
biopsies indirectly reﬂect a larger volume of tumour.When
this is present in small prostates, there is a higher possibility of
exposing this tumour during dissection. In contrast, the larger
amount of benign tissues in medium-sized and large glands
decreases the chances of tumour exposure. Furthermore, the
risk of having PSM is almost three-fold if NSS is performed.
This higher rate of PSM after NSS could be attributed to
surgical technique or tumour behaviour [25]. The increased
lateral PSM supports the theory of an increased temptation to
dissect closer to the prostate for better neurovascular bundle
preservation when operating on a small prostate. There is a
lesser tendency to dissect closer to the prostate in larger
glands because of more limited space to manoeuvre. Also,
there were more high-grade tumours in small prostates
indicating their more aggressive tendency. The mean tumour
volumes were similar, which implies that the same volume
of tumour was housed in the smaller prostates, thereby
increasing the likelihood of exposing them during dissection.
Finally, compared with large glands wherein the demarcation
between the prostate and urethra are more pronounced, we
think that in small prostates, it is more diﬃcult to identify the
prostato-urethral junction. This accounts for the increased
apical PSM for small prostates in our present data.
While it seems logical to assume that an increase in PSM in
small prostates will lead to increase in BCR, there are
conﬂicting reports about the relationship between prostate size
and BCR. In a previous article, Anastasiou et al. [26] reported
that a lower prostate weight protects against BCR, while
Labanaris et al. [23] reported the opposite to be true. In our
present study, a small prostate size was indirectly related
to BCR because in the presence of PSM, a PSA level of
>20 ng/dL was a predictor of BCR. Also, in our present study,
no preoperative factors predicted BCR in glands weighing
31–45 and >45 g. Variables other than PSM can inﬂuence
BCR [27]. In our present study, preoperative factors, such as T
stage and biopsy Gleason score, were predictors of BCR for
prostates in the 31–45 and >45 g groups. Other pathological
factors, such as lymph node metastasis which were not the
focus of our present study, could have easily inﬂuenced the
occurrence of BCR in these larger glands.
Given the present ﬁndings, we think that the presence
preoperatively of ≥3 positive biopsy cores and T3 stage
tumour in smaller glands should be given importance during
surgical planning and patient counselling. Intraoperatively,
aside from performing meticulous dissection of the prostate
and neurovascular bundle, it might be wise to send more
specimens for frozen-section analysis in RARP done on small
prostates [28,29]. For those patients who have a preoperative
PSA level of >20 ng/dL and are found to have PSM, a closer
Table 4 Multivariate analysis of preoperative predictors of BCR in cases with PSM.
Characteristics Prostate size <31 g Prostate size 31–45 g Prostate size >45 g
Univariate analysis Multivariate analysis Univariate analysis Univariate analysis
OR (95% CI), P OR (95% CI), P OR (95% CI), P OR (95% CI), P
PSA level (ng/dL):
>10 1.37 (0.4–4.9), 0.632 – 2.92 (0.7–12.3), 0.146 1.53 (0.3–7.9), 0.614
>20 5.25 (1.4–28.4), 0.017* 5.34 (1.3–22.2), 0.021* 3.64 (0.8–17.0), 0.100 2.83 (0.5–12.0), 0.221
Biopsy Gleason score:
≥7 0.53 (0.1–1.9), 0.337 – 3.67 (0.4–35.9), 0.265 2.31 (0.4–13.9), 0.363
≥8 0.71 (0.2–2.4), 0.593 – 7.33 (0.8–68.5), 0.080 3.27 (0.5–19.7), 0.196
Clinical T stage:
≥T2 1.56 (0.4–5.6), 0.499 – 2.20 (0.4–13.0), 0.385 2.31 (0.4–13.9), 0.363
T3 3.82 (1.0–13.9), 0.043* 3.89 (0.9–15.7), 0.056 1.76 (0.4–7.1), 0.431 2.87 (0.4–11.9), 0.325
D’Amico risk:
≥Intermediate 0.66 (0.1–4.5), 0.672 – 1.83 (0.3–11.3), 0.513 0.17 (0.01–2.2), 0.172
High 0.55 (0.1–2.1), 0.389 – 0.94 (0.2–3.9), 0.930 1.21 (0.2–6.6), 0.824
Positive biopsy cores ≥3† 1.75 (0.2–12.2), 0.601 – 0.72 (0.18–2.9), 0.643 1.53 (0.3–7.9), 0.614
Maximum % cancer per biopsy
core
>25 2.75 (0.5–14.9), 0.240 – 1.84 (0.4–8.0), 0.416 0.18 (0.01–2.3), 0.187
>50 3.33 (0.8–14.6), 0.110 – 2.22 (0.5–10.7), 0.319 0.20 (0.03–1.2), 0.070
>75 0.83 (0.2–3.8), 0.804 – 2.00 (0.5–8.5), 0.349 0.14 (0.01–1.4), 0.096
EPE on MRI 0.76 (0.2–2.6), 0.659 – 0.40 (0.1–1.7), 0.223 0.93 (0.2–4.9), 0.935
*Signiﬁcant; †Median-split; ‡Multivariate analysis not performed.
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follow-up scheme should be instituted and a lower threshold
for adjuvant therapy may be in order. The apparent absence of
preoperative factors to predict PSM in larger glands and BCR
in larger glands with PSM warrants further investigation into
factors that are not available preoperatively.
The present study is limited by the fact that it is from a single
institution with a high case volume and thus our results may
not be representative of cases done in other centres with fewer
cases. Also, the oncological outcome data contained in the
present series were taken from the results of operations
performed by one surgeon who has done >1000 RARPs and
might therefore not be readily applicable to surgeons with
less experience using this approach. Furthermore, a better
association between prostate size and BCR as well as survival
rates would beneﬁt from a more detailed investigation after a
longer follow-up period. Further studies on the eﬀect of
prostate size on other outcomes after RARP, such as functional
outcomes, are still needed.
In conclusion, the present study established certain
preoperative predictive factors for PSM and BCR based
on prostate gland size. Regardless of tumour stage and
performance of NSS, men with smaller prostates have higher
grade cancer and a greater likelihood of having PSM. The
preoperative presence of ≥3 positive biopsy cores in a small
prostate predicted PSM regardless of Gleason score. For
small prostates who exhibit PSM on pathological analysis, a
preoperative PSA level of >20 ng/dL is predictive of BCR.
These factors can be used for preoperative planning, patient
counselling and postoperative evaluation.
Conflicts of Interest
The authors of this article have no conﬂicts of interest to
disclose.
References
1 Koutlidis N, Mourey E, Champigneulle J, Mangin P, Cormier L.
Robot-assisted or pure laparoscopic nerve-sparing radical prostatectomy:
what is the optimal procedure for the surgical margins? A single center
experience. Int J Urol 2012; 19: 1076–81
2 Freedland SJ, Isaacs WB, Platz EA et al. Prostate size and risk of
high-grade, advanced prostate cancer and biochemical progression after
radical prostatectomy: a search database study. J Clin Oncol 2005; 23:
7546–54
3 Chan RC, Barocas DA, Chang SS et al. Eﬀect of a large prostate gland on
open and robotically assisted laparoscopic radical prostatectomy. BJU Int
2008; 101: 1140–4
4 Pettus JA, Masterson T, Sokol A et al. Prostate size is associated with
surgical diﬃculty but not functional outcome at 1 year after radical
prostatectomy. J Urol 2009; 182: 949–55
5 Pierorazio PM, Kinnaman MD, Wosnitzer MS, Benson MC, McKiernan
JM, Goluboﬀ ET. Prostate volume and pathologic prostate cancer
outcomes after radical prostatectomy. Urology 2007; 70: 696–701
6 Frota R, Turna B, Santos BM, Lin YC, Gill IS, Aron M. The eﬀect of
prostate weight on the outcomes of laparoscopic radical prostatectomy.
BJU Int 2008; 101: 589–93
7 Newton MR, Phillips S, Chang SS et al. Smaller prostate size predicts
high grade prostate cancer at ﬁnal pathology. J Urol 2010; 184: 930–7
8 Dasgupta P, Patil K, Anderson C, Kirby R. Transition from open to
robotic-assisted radical prostatectomy. BJU Int 2008; 101: 667–8
9 Ficarra V, Novara G, Artibani W et al. Retropubic, laparoscopic, and
robot-assisted radical prostatectomy: a systematic review and cumulative
analysis of comparative studies. Eur Urol 2009; 55: 1037–63
10 Jeong W, Araki M, Park SY et al. Robot-assisted laparoscopic radical
prostatectomy in the Asian population: modiﬁed port conﬁguration and
ultradissection. Int J Urol 2010; 17: 297–300
11 Link BA, Nelson R, Josephson DY et al. The impact of prostate gland
weight in robot assisted laparoscopic radical prostatectomy. J Urol 2008;
180: 928–32
12 Hong SK, Yu JH, Han BK et al. Association of prostate size and tumor
grade in Korean men with clinically localized prostate cancer. Urology
2007; 70: 91–5
13 Levinson AW, Ward NT, Sulman A et al. The impact of prostate size on
perioperative outcomes in a large laparoscopic radical prostatectomy
series. J Endourol 2009; 23: 147–52
14 Kopp RP, Han M, Partin AW, Humphreys E, Freedland SJ, Parsons JK.
Obesity and prostate enlargement in men with localized prostate cancer.
BJU Int 2011; 108: 1750–5
15 Freedland SJ, Sun L, Kane CJ et al. Obesity and oncological outcome
after radical prostatectomy: impact of prostate-speciﬁc antigen-based
prostate cancer screening: results from the Shared Equal Access Regional
Cancer Hospital and Duke Prostate Center databases. BJU Int 2008; 102:
969–74
16 Yong DZ, Tsivian M, Zilberman DE, Ferrandino MN, Mouraviev V,
Albala DM. Predictors of prolonged operative time during robot-assisted
laparoscopic radical prostatectomy. BJU Int 2011; 107: 280–2
17 Boczko J, Erturk E, Golijanin D, Madeb R, Patel H, Joseph JV. Impact
of prostate size in robot-assisted radical prostatectomy. J Endourol 2007;
21: 184–8
18 Marchetti PE, Shikanov S, Razmaria AA, Zagaja GP, Shalhav AL.
Impact of prostate weight on probability of positive surgical margins in
patients with low-risk prostate cancer after robotic-assisted laparoscopic
radical prostatectomy. Urology 2011; 77: 677–81
19 Skolarus TA, Hedgepeth RC, Zhang Y et al. Does robotic technology
mitigate the challenges of large prostate size? Urology 2010; 76:
1117–21
20 Ficarra V, Novara G, Secco S et al. Predictors of positive surgical
margins after laparoscopic robot assisted radical prostatectomy. J Urol
2009; 182: 2682–8
21 Atug F, Castle EP, Srivastav SK, Burgess SV, Thomas R, Davis R.
Positive surgical margins in robotic-assisted radical prostatectomy: impact
of learning curve on oncologic outcomes. Eur Urol 2006; 49: 866–71
22 Yadav R, Tu JJ, Jhaveri J, Leung RA, Rao S, Tewari AK. Prostate volume
and the incidence of extraprostatic extension: is there a relation?
J Endourol 2009; 23: 383–6
23 Labanaris AP, Zugor V, Witt JH. Robot-assisted radical prostatectomy in
patients with a pathologic prostate specimen weight ≥100 grams versus
≤50 grams: surgical, oncologic and short-term functional outcomes. Urol
Int 2013; 90: 24–30
24 Coelho RF, Chauhan S, Orvieto MA, Palmer KJ, Rocco B, Patel VR.
Predictive factors for positive surgical margins and their locations after
robot-assisted laparoscopic radical prostatectomy. Eur Urol 2010; 57:
1022–9
25 Røder MA, Thomsen FB, Berg KD et al. Risk of biochemical recurrence
and positive surgical margins in patients with pT2 prostate cancer
undergoing radical prostatectomy. J Surg Oncol 2014; 109: 132–8
26 Anastasiou I, Tyritzis SI, Adamakis I et al. Prognostic factors identifying
biochemical recurrence in patients with positive margins after radical
prostatectomy. Int Urol Nephrol 2011; 43: 715–20
Prostate size and PSM rates after RARP
© 2014 The Authors
BJU International © 2014 BJU International 7
27 Yossepowitch O, Briganti A, Eastham JA et al. Positive surgical margins
after radical prostatectomy: a systematic review and contemporary
update. Eur Urol 2014; 65: 303–13
28 Goharderakhshan RZ, Sudilovsky D, Carroll LA, Grossfeld GD, Marn
R, Carroll PR. Utility of intraoperative frozen section analysis of surgical
margins in region of neurovascular bundles at radical prostatectomy.
Urology 2002; 59: 709–14
29 Schlomm T, Tennstedt P, Huxhold C et al. Neurovascular
structure-adjacent frozen-section examination (NeuroSAFE) increases
nerve-sparing frequency and reduces positive surgical margins in open
and robot-assisted laparoscopic radical prostatectomy: experience after
11,069 consecutive patients. Eur Urol 2012; 62: 333–40
Correspondence: Koon Ho Rha, Department of Urology and
Urological Science Institute, Yonsei University College of
Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752,
Republic of Korea.
e-mail: khrha@yuhs.ac
Abbreviations: BCR, biochemical recurrence; EPE,
extraprostatic extension; NSS, nerve-sparing surgery; PSM,
positive surgical margin; (RA)RP, (robot-assisted) radical
prostatectomy.
Tuliao et al.
© 2014 The Authors
8 BJU International © 2014 BJU International
